Sintia Teichman

Sixty Degree Capital thesis

Headqaurters: San Francisco, CA, USA Subsector: MedTech Everside Health Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Everside Health’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Everside Health’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administra

Sector and stage focus

• Seed: Pharmaceuticals, Health IT, Health & Hospital Services
• Series B: Pharmaceuticals, Health & Hospital Services, Health IT
• Series A: Pharmaceuticals, Health IT, Health & Hospital Services
• general: British Columbia

Is Sintia Teichman a fit for your round?

Upload your pitch deck and see whether Sintia Teichman appears in your top 20 matches.